Patents by Inventor Lola M. Reid
Lola M. Reid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180295834Abstract: Human biliary tree stem/progenitors (hBTSCs) are being used for cell therapies of patients with liver cirrhosis. A cryopreservation method was established to optimize sourcing of hBTSCs for these clinical programs and that comprises serum-free Kubota's Medium (KM) supplemented with 10% dimethyl sulfoxide (DMSO), ˜3% recombinant human albumin and 0.1% hyaluronans. Cryopreserved versus freshly isolated hBTSCs were similar in vitro with respect to self-replication, stemness traits, and multipotency. They were able to differentiate to functional hepatocytes, cholangiocytes or pancreatic islets, yielding similar levels of secretion of albumin or of glucose-inducible levels of insulin. Cryopreserved versus freshly isolated hBTSCs were equally able to engraft into immunocompromised mice yielding cells with human-specific gene expression and human albumin levels in murine serum that were higher for cryopreserved than for freshly isolated hBTSCs.Type: ApplicationFiled: April 4, 2018Publication date: October 18, 2018Applicants: The University of North Carolina at Chapel Hill, Sapienza Universita di RomaInventors: Lola M. Reid, Alvaro Domenico, Vincenzo Cardinale, Eugenio Gaudio, Guido Carpino
-
Patent number: 10093895Abstract: The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1+, VCAM-1+, ?3-integrin+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle ?-actin, nestin, hepatocyte growth factor, stromal derived factor-1? and Hlx homeobox transcriptional factor.Type: GrantFiled: July 8, 2016Date of Patent: October 9, 2018Assignee: The University of North Carolina at Chapel HillInventors: Hiroshi Kubota, Lola M. Reid
-
Publication number: 20170369849Abstract: The present disclosure provides methods for producing bioengineered tissue along with an apparatus and other relevant compositions employed in generation thereof.Type: ApplicationFiled: May 3, 2017Publication date: December 28, 2017Applicant: The University of North Carolina at Chapel HillInventors: Ariel Dawn HANSON, Mitsuo YAMAUCHI, Eliane Lucie WAUTHIER, Timothy Anh-Hieu DINH, Praveen SETHUPATHY, Lola M. REID
-
Patent number: 9750770Abstract: A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted.Type: GrantFiled: November 9, 2015Date of Patent: September 5, 2017Assignees: The University of North Carolina at Chapel Hill, University of Miami-Diabetes Research Institute, Sapienza Università Di RomaInventors: Lola M. Reid, Yunfang Wang, David A. Gerber, Giacomo Lanzoni, Luca Inverardi, Juan Dominguez-Bendala, Domenico Alvaro, Vincenzo Cardinale, Eugenio Gaudio, Guido Carpino
-
Publication number: 20170152472Abstract: The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1+, VCAM-1+, ?3-integrin+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle ?-actin, nestin, hepatocyte growth factor, stromal derived factor-1? and Hlx homeobox transcriptional factor.Type: ApplicationFiled: July 8, 2016Publication date: June 1, 2017Applicant: University of North Carolina at Chapel HillInventors: Hiroshi KUBOTA, Lola M. REID
-
Patent number: 9625450Abstract: A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters.Type: GrantFiled: April 3, 2014Date of Patent: April 18, 2017Assignee: The University of North Carolina at Chapel HillInventors: Hiroshi Kubota, Lola M. Reid
-
Publication number: 20170096641Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: ApplicationFiled: October 12, 2016Publication date: April 6, 2017Applicants: Vesta Therapeutics Inc., University of North Carolina at Chapel HillInventors: Lola M. REID, Nicholas MOSS, Mark E. FURTH, John W. LUDLOW, Andrew T. BRUCE
-
Patent number: 9533013Abstract: A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted.Type: GrantFiled: March 12, 2014Date of Patent: January 3, 2017Assignees: University of North Carolina at Chapel Hill, Sapienza Università Di Roma, University of Miami—Diabetes Research InstituteInventors: Lola M. Reid, Yunfang Wang, David A. Gerber, Giacomo Lanzoni, Luca Inverardi, Juan Dominguez-Bendala, Domenico Alvaro, Vincenzo Cardinale, Eugenio Gaudio, Guido Carpino
-
Publication number: 20160257937Abstract: The present disclosure provides a model of human fibrolamellar hepatocellular carcinoma (FL-HCC) cells maintained as a transplantable tumor line in a host and a method to establish a transplantable human FL-HCC tumor line. Methods of ex vivo cultures of the FL-HCC are provided. Methods of diagnosing and treating FL-HCC tumors are also provided.Type: ApplicationFiled: March 4, 2016Publication date: September 8, 2016Applicant: University of North Carolina at Chapel HillInventors: Eliane WAUTHIER, Tsunekazu OIKAWA, Timothy Anh-Hieu DINH, Praveen SETHUPATHY, Lola M. REID
-
Patent number: 9416349Abstract: The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1+, VCAM-1+, ?3-integrin+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle ?-actin, nestin, hepatocyte growth factor, stromal derived factor-1? and Hlx homeobox transcriptional factor.Type: GrantFiled: July 21, 2014Date of Patent: August 16, 2016Assignee: University of North Carolina at Chapel HillInventors: Hiroshi Kubota, Lola M. Reid
-
Publication number: 20160058798Abstract: A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted.Type: ApplicationFiled: November 9, 2015Publication date: March 3, 2016Applicants: University of North Carolina at Chapel Hill, Sapienza Università di Roma, University of MiamiInventors: Lola M. REID, Yunfang WANG, David A. GERBER, Giacomo LANZONI, Luca INVERARDI, Juan DOMINGUEZ-BENDALA, Domenico ALVARO, Vincenzo CARDINALE, Eugenio GAUDIO, Guido CARPINO
-
Publication number: 20150093762Abstract: The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1+, VCAM-1+, ?3-integrin+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle ?-actin, nestin, hepatocyte growth factor, stromal derived factor-1? and Hlx homeobox transcriptional factor.Type: ApplicationFiled: July 21, 2014Publication date: April 2, 2015Applicant: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: HIROSHI KUBOTA, LOLA M. REID
-
Publication number: 20140301985Abstract: A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted.Type: ApplicationFiled: March 12, 2014Publication date: October 9, 2014Applicants: University of North Carolina at Chapel Hill, Sapienza Università di Roma, Diabetes Research InstituteInventors: Lola M. REID, Yunfang WANG, David A. GERBER, Giacomo LANZONI, Luca INVERARDI, Juan DOMINGUEZ-BENDALA, Domenico ALVARO, Vincenzo CARDINALE, Eugenio GAUDIO, Guido CARPINO
-
Publication number: 20140302547Abstract: A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters.Type: ApplicationFiled: April 3, 2014Publication date: October 9, 2014Applicant: University of North Carolina at Chapel HillInventors: HIROSHI KUBOTA, Lola M. Reid
-
Publication number: 20140302601Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: ApplicationFiled: April 3, 2014Publication date: October 9, 2014Applicants: University of North Carolina at Chapel Hill, Vesta Therapeutics Inc.Inventors: Lola M. REID, Nicholas MOSS, Mark E. FURTH, John W. LUDLOW, Andrew T. BRUCE
-
Patent number: 8709800Abstract: A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters.Type: GrantFiled: November 5, 2008Date of Patent: April 29, 2014Assignee: University of North Carolina at Chapel HillInventors: Hiroshi Kubota, Lola M. Reid
-
Patent number: 8691579Abstract: A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters.Type: GrantFiled: December 2, 2008Date of Patent: April 8, 2014Assignee: University of North Carolina at Chapel HillInventors: Hiroshi Kubota, Lola M. Reid
-
Patent number: 8691523Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: GrantFiled: December 12, 2006Date of Patent: April 8, 2014Assignees: Vesta Therapeautics, Inc., University of North Carolina at Chapel HillInventors: Lola M. Reid, Nicholas Moss, Mark E. Furth, John W. Ludlow, Andrew T. Bruce
-
Patent number: 8404483Abstract: A method is provided for controlling the survival, proliferation, and/or differentiation of hepatic progenitors in vitro by using specific types of mesenchymal feeder cells or one of more of the paracrine signals produced by those feeders.Type: GrantFiled: September 10, 2010Date of Patent: March 26, 2013Assignee: University of North Carolina at Chapel HillInventors: Lola M. Reid, Randall E. McClelland, Joshua Uronis, Hsin-Lei Yao, Eliane Wauthier
-
Publication number: 20130071834Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.Type: ApplicationFiled: June 29, 2012Publication date: March 21, 2013Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Ann Kwong, Randal Byrn, Lola M. Reid